Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Prevalence of persistent central-involved diabetic macular edema (DME) through 24 weeks of anti–vascular endothelial growth factor therapy and its longer-term outcomes may be relevant to treatment. OBJECTIVE: To assess outcomes of DME persisting at least 24 weeks after randomization to t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Ophthalmol
Päätekijät: Bressler, Neil M., Beaulieu, Wesley T., Glassman, Adam R., Blinder, Kevin J., Bressler, Susan B., Jampol, Lee M., Melia, Michele, Wells, John A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2018
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885906/
https://ncbi.nlm.nih.gov/pubmed/29392288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2017.6565
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia